| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC10276 | C29 Featured | C29 is a potential TLR2 inhibitor. |
|
| DC11493 | C2BA-4 | C2BA-4(C2BA 4) is a potent, specific human Pregnane X receptor (hPXR) activator with EC50 of 49 nM. |
|
| DC20327 | C450-0730 | C450-0730 is a potent LuxN antagonist that antagonizes LuxN-AI-1 binding with IC50 of 2.7 uM. |
|
| DC20328 | C5-benzyl SAHA | C5-benzyl SAHA is a C5-modified SAHA analog that displays dual selectivity to HDAC6 (IC50=0.27 uM) and HDAC8 (IC50=0.38 uM) over HDAC 1, 2, and 3 (IC50=2.9-5.8 uM). |
|
| DC7658 | C646 Featured | C646 is an inhibitor for histone acetyltransferase, and inhibits p300 with a Ki of 400 nM. Preferentially selective for p300 versus other acetyltransferases. |
|
| DC9528 | C75 (trans) Featured | C75 trans is the trans form of C75; C75 is a potent fatty-acid synthase(FASN) inhibitor with IC50 of 35.4 μM(LNCaP cell Proliferation inhibition). |
|
| DC10419 | C 87 | C87 is a novel small-molecule TNFα inhibitor; potently inhibits TNFα-induced cytotoxicity with an IC50 of 8.73 μM. |
|
| DC7697 | CA-074-Me Featured | CA-074 Me is a selective and cell-permeable inhibitor of cathepsin B. |
|
| DC10330 | PD-1-IN-17 Featured | PD-1-IN-17 has CAS#CAS:1673560-66-1, which is a programmed cell death-1 (PD-1) inhibitor. PD-1-IN-17 was first reported in patent WO2015033301A1, (Compound 4), inhibits 92% splenocyte proliferation at 100 nM. PD-1-IN-17 may be related to CA-170 (AUPM170), which is a potent PD-1 inhibitor and curreently under clinical trials. |
|
| DC8704 | Ca2+ channel agonist 1 | Ca2+ channel agonist 1 is a N-type Ca2+ channel activity agonist, with EC50 of 14.23 uM, also inhibits cdk2 kinase activity with EC50 of 3.34 uM. |
|
| DC10648 | CA4948-Analog Featured | CA4948-Analog is an analog of Emavusertib. It has similar property to CA-4948, which is a potent, and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. It was reported in patent WO 2015104688. Emavusertib, also known as CA-4948 i |
|
| DC12044 | CA-5f Featured | CA-5f is a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer. |
|
| DC4186 | Cabazitaxel | Cabazitaxel (Jevtana, XRP6258) is a semi-synthetic derivative of a natural taxoid. |
|
| DC9423 | Cabergoline | Cabergoline, an ergot derivative, is a potent dopamine receptor agonist on D2 receptors. |
|
| DC26013 | Cabotegravir Sodium Featured | Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection. |
|
| DC8180 | Cabotegravir(GSK744) Featured | Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection. |
|
| DC9266 | Cabozantinib S-malate Featured | Cabozantinib S-malate (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively. |
|
| DC10736 | CaCC(inh)-A01 Featured | CaCC(inh)-A01 is a non-selective inhibitor of calcium-activated chloride channels (CaCCs) that blocks ATP-stimulated chloride conductance in human salivary gland, intestinal, and bronchial epithelium (mean IC50 = 10 µM). |
|
| DC20856 | CAD-031 Featured | CAD-031 (CAD31) is a novel brain penetrant, J147-derivative that has enhanced neurogenic activity over J147 in human neural precursor cells (NPCs). |
|
| DC10457 | Cadazolid (ACT-179811) Featured | Cadazolid (ACT-179811) is a novel fluoroquinolone-oxazolidinone antibiotic and a protein synthesis inhibitor. |
|
| DC5068 | Idelalisib (CAL-101,GS-1101) Featured | CAL-101 is a selective p110δ inhibitor with IC50 of 2.5 nM; shown to have 40- to 300-fold greater selectivity for p110δ thanp110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. |
|
| DCAPI1559 | Calcifediol Featured | Calcifediol is a major circulating metabolite of vitamin D3, acting as a competitive inhibitor with an apparent Ki of 3.9 μM, suppresses PTH secretion and mRNA (ED50=2 nM). |
|
| DCAPI1415 | Calcipotriol(Calcipotriene) Featured | Calcipotriol is a synthetic VitD3 analogue with a high affinity for the vitamin D receptor. |
|
| DC10327 | Calcitonin salmon Featured | Calcitonin, Salmon is a calcium regulating hormone secreted from mammalian thyroid parafollicular cells and in non-mammalian species from the ultimobranchial gland. |
|
| DCAPI1150 | Calcitriol (Rocaltrol) Featured | Calcitriol is the most active metabolite of vitamin D and also a vitamin D receptor (VDR) agonist. |
|
| DCAPI1351 | Calcium levofolinate (Calcium Folinate) | Calcium levofolinate (Calcium Folinate) |
|
| DC12253 | Calcium polystyrene sulfonate (Poly(styrenesulfonic acid) calcium salt) | Calcium polystyrene sulfonate is an ion-exchange resin used for reducing blood levels of potassium. Calcium polystyrene sulfonate is used to treat hyperkalemia in patients with chronic kidney disease (CKD). |
|
| DC9386 | Calcium-Sensing Receptor Antagonists I | Calcium-Sensing Receptor Antagonists I is an antagonist of calcium-sensing parathyroid hormone receptors. |
|
| DC20857 | Calhex-231 Featured | Calhex-231 is a potent negative allosteric modulator of CaSR that blocks calcium-mediated activation with IC50 of 0.39 uM. |
|
| DC20329 | Calindol hydrochloride | Calindol hydrochloride is a calcimimetic acting agent and positive allosteric modulator (agonist) of CaSR with EC50 of 0.31 uM (stimulated 3H IP accumulation in CHO cells at 2 mM Ca2+). |
|
